Tg Therapeutics (TGTX) Gross Margin (2021 - 2025)
Historic Gross Margin for Tg Therapeutics (TGTX) over the last 5 years, with Q3 2025 value amounting to 82.63%.
- Tg Therapeutics' Gross Margin fell 62400.0% to 82.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 85.34%, marking a year-over-year decrease of 29700.0%. This contributed to the annual value of 88.3% for FY2024, which is 56500.0% down from last year.
- As of Q3 2025, Tg Therapeutics' Gross Margin stood at 82.63%, which was down 62400.0% from 86.58% recorded in Q2 2025.
- In the past 5 years, Tg Therapeutics' Gross Margin registered a high of 97.88% during Q3 2023, and its lowest value of 82.14% during Q4 2023.
- Its 5-year average for Gross Margin is 88.92%, with a median of 88.4% in 2024.
- Per our database at Business Quant, Tg Therapeutics' Gross Margin tumbled by -141100bps in 2023 and then surged by 36300bps in 2024.
- Quarter analysis of 5 years shows Tg Therapeutics' Gross Margin stood at 82.47% in 2021, then grew by 17bps to 96.25% in 2022, then dropped by -15bps to 82.14% in 2023, then rose by 4bps to 85.77% in 2024, then decreased by -4bps to 82.63% in 2025.
- Its last three reported values are 82.63% in Q3 2025, 86.58% for Q2 2025, and 87.14% during Q1 2025.